KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed EBT Margin for 4 consecutive years, with 546.48% as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, EBT Margin rose 46283.0% year-over-year to 546.48%, compared with a TTM value of 412.06% through Dec 2023, up 3202.0%, and an annual FY2024 reading of 582455.32%, down 37769522.0% over the prior year.
  • EBT Margin was 546.48% for Q3 2023 at Ginkgo Bioworks Holdings, down from 215.03% in the prior quarter.
  • Across five years, EBT Margin topped out at 10078.14% in Q4 2020 and bottomed at 1171.38% in Q4 2021.
  • Average EBT Margin over 4 years is 397.51%, with a median of 253.88% recorded in 2023.
  • The sharpest move saw EBT Margin plummeted -1124951bps in 2021, then skyrocketed 98025bps in 2022.
  • Year by year, EBT Margin stood at 10078.14% in 2020, then plummeted by -112bps to 1171.38% in 2021, then skyrocketed by 84bps to 191.13% in 2022, then crashed by -186bps to 546.48% in 2023.
  • Business Quant data shows EBT Margin for DNA at 546.48% in Q3 2023, 215.03% in Q2 2023, and 253.88% in Q1 2023.